Valion Bio, Inc. — Form 8-K
Filed September 1, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
On August 31, 2026, 3i LP closed a $7.74M investment in Valion Bio: $100K in Series B Preferred Shares (100 shares) with warrants for 3,077 common shares at $3.62/share; and $7.637M in Series C Preferred Shares (7,637 shares) with warrants for 1,053,969 common shares at $3.62/share. Of this amount, $6.137M satisfied overdue cash true-up obligations, $100K covered legal fees, and $1.5M was paid to the company. Separately, Lisa Wolf was promoted from CFO to President and COO (retaining CFO duties) following Michael K. Handley's departure as CEO; board directors Jared Malbin and Thomas Jensen were appointed.
Why this rating
Investment equals 194% of company's $4M market cap; provides near-term liquidity ($1.5M cash). Leadership restructuring under going-concern pressure is material but Wolf's appointment suggests investor confidence. Dilutive warrant package (1.06M shares) and overdue obligations indicate financial stress, offsetting positive aspects.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $3.26 ▼ 8.68% | at our read · unknown $3.57 | +10 min · unknown $3.57 ▲ 0.00% | +30 min · unknown $3.57 ▲ 0.00% | +1 hr · unknown $3.57 ▲ 0.00% | +4 hrs · unknown $3.23 ▼ 9.52% |
The stock had already moved +9.51% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.